ライフサイエンスコーパス: hepatitis B

1 good alternative to TDF for treating chronic hepatitis B.

2 curative antiviral therapies against chronic hepatitis B.

3 be infected by intact virions of transgenic hepatitis B.

4 , which may open a new venue to cure chronic hepatitis B.

5 -born African Americans (FBAAs) with chronic hepatitis B.

6 NKG2D axis in T cell/NK cell interactions in hepatitis B.

7 tiviral therapeutics for the cure of chronic hepatitis B.

8 eseeable therapeutic developments in chronic hepatitis B.

9 metastatic progression in HCC patients with hepatitis B.

10 samples from patients with acute and chronic hepatitis B.

11 Chronic hepatitis B affects over 300 million people who are at r

12 V reactivation and graft loss from recurrent hepatitis B after liver transplantation in patients with

13 titis B recurrence for patients with chronic hepatitis B after liver transplantation.

14 ents infected during adulthood develop acute hepatitis B (AHB), which usually results in viral cleara

15 ieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortality due t

16 nd C and a 65% reduction in mortality due to hepatitis B and C by 2030.

17 Liver Diseases Curriculum and Training-First Hepatitis B and C curriculums as well as in LiverLearnin

18 sitive status, donation after cardiac death, hepatitis B and C seropositive status, cigarette use, di

19 Aflatoxin B1 (AFB1) and/or hepatitis B and C viruses are risk factors for human hep

20 cell leukemia virus, human papilloma virus, hepatitis B and C viruses, herpes simplex virus, norovir

21 tients registered in the Danish Database for Hepatitis B and C with CHC and a liver fibrosis assessme

22 Chronic hepatitis B and D infections are major causes of liver d

23 er for bile acids (BAs) and the receptor for hepatitis B and D viruses.

24 oma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal.

25 urden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections.

26 panded spectrum of activity that also covers hepatitis B and herpes viruses.

27 hepatitis C, 67 [65%] of 103 individuals for hepatitis B, and 133 [51%] of 263 individuals for latent

28 phtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haemophilus influenzae type b) and pneu

29 A biosensor for the detection of hepatitis B antibodies in clinical saliva was developed.

30 The detection of minute amounts of hepatitis B antibodies was performed by plasmonically am

31 ld Health Organization resolved to eliminate hepatitis B as a public health threat by 2030.

32 ies donors at increased risk of transmitting hepatitis B, C, and human immunodeficiency virus.

33 o antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNAs are ac

34 Chronic hepatitis B (CHB) exhibits a variety of clinical outcome

35 Chronic hepatitis B (CHB) has become a treatable and controllabl

36 difficult to study in patients with chronic hepatitis B (CHB) infection.

37 Chronic hepatitis B (CHB) is characterized by hepatic inflammati

38 responses to IFN-alpha treatment of chronic hepatitis B (CHB) patients is influenced by IFN-induced

39 Patients with chronic hepatitis B (CHB) usually acquire the virus perinatally,

40 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred in Chin

41 Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (NAs) sup

42 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated ci

43 alog (NA) treatment in patients with chronic hepatitis B (CHB).

44 control of viral replication during chronic hepatitis B (cHBV) infection, but little is known of the

45 We excluded patients if they were hepatitis B-co-infected or hepatitis C-co-infected, had

46 ciated with the baseline serostatus (+ or -: hepatitis B core [HBc], hepatitis C virus [HCV], Epstein

47 ng severity, even in the setting of isolated hepatitis B core antibody, with or without accompanying

48 1 occurred in a patient known to be isolated hepatitis B core antibody-positive.

49 rsons age 6 years and older for: antibody to hepatitis B core antigen (anti-HBc), indicative of previ

50 recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipien

51 urface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive patients af

52 rus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV

53 %-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%-7

54 0.14-0.32) versus patients with antibody to hepatitis B core antigen only.

55 re likely to be HCV and antibody reacting to hepatitis B core antigen+, and less likely to have diabe

56 en (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B su

57 actions between the viral pre-genome and the hepatitis B core protein that play roles in defining the

58 The peak levels of hepatitis B virus DNA and hepatitis B core-related antigen after cessation of ther

59 guide the design of clinical trials aimed at hepatitis B cure.

60 (HBsAg-positive) for posttest counseling and hepatitis B-directed care.

61 iral life cycle, with production of HBV DNA, hepatitis B e (HBe), core (HBc) and surface (HBs) antige

62 fected with CHB, among whom, 28.6% were also hepatitis B e antigen (HBeAg) positive.

63 study was to identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to ant

64 uation, being relatively higher in initially hepatitis B e antigen (HBeAg)-positive patients (62.5%,

65 Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B

66 aged 18-55 years, who were treatment naive, hepatitis B e antigen [HBeAg] negative, anti-hepatitis D

67 pping versus continuing antiviral therapy in hepatitis B e antigen-negative patients, monotherapy ver

68 Maternal hepatitis B e-antigen (HBeAg) and high viral load have b

69 Meeting goals for hepatitis B elimination will require increased vaccinati

70 ir carriers to control infections with human hepatitis B (HBV) and C (HCV) viruses.

71 erformed to investigate the relationships of hepatitis B (HBV) and hepatitis C virus (HCV) infection

72 y, we estimated the point prevalence of HIV, hepatitis B (HBV), and hepatitis C (HCV) in people with

73 Hepatitis B immune globulin (HBIG) has been an integral

74 In addition to hepatitis B immune globulin and vaccination, oral antivi

75 use of oral antiviral therapy alone without hepatitis B immune globulin for chronic hepatitis B pati

76 Oral antiviral therapy alone without hepatitis B immune globulin is highly effective in preve

77 s treated with entecavir monotherapy without hepatitis B immune globulin.

78 n still develops in children after universal hepatitis B immunization.

79 iplicative effects of aflatoxin exposure and hepatitis B in causing HCC.

80 , based on three national serosurvey data of hepatitis B in China, we propose an age- and time-depend

81 liver disease, and elimination strategies of hepatitis B in sub-Saharan Africa.

82 Chronic hepatitis B infection (HBV) is major cause of morbidity

83 Chronic hepatitis B infection affects >300 million people worldw

84 ar carcinoma (HCC) that is highly related to hepatitis B infection and aflatoxin B1.

85 -viral immunity as first line defense during hepatitis B infection, particularly in untreated patient

86 treating adolescents and adults with chronic hepatitis B infection.

87 ing among a national cohort of veterans with hepatitis B infection; antiviral therapy and liver imagi

88 , we designed and implemented a new model of hepatitis B: infectious transgenic hepatitis B virus com

89 persistent infection in people with chronic hepatitis B, leading to accelerated progression of liver

90 long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with ent

91 strate the usefulness of this new transgenic hepatitis B model.

92 duction of these novel compounds for chronic hepatitis B necessitates a standardized appraisal of the

93 diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver diseases (NAFLD);

94 Randomisation was stratified by viral hepatitis B or C coinfection and computer-generated.

95 c inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepatitis, ha

96 eening HIV-1 RNA value and co-infection with hepatitis B or C.

97 inically significant cardiovascular disease, hepatitis B or hepatitis C viral infection, and a known

98 ment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear.

99 ellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent

100 hout hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine (LAM) r

101 Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-R mutati

102 study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who receive

103 ar 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with compens

104 ic activity compared with those from chronic hepatitis B patients, which were mainly mediated by incr

105 shingles, cold sores, mononucleosis, mumps, hepatitis B, plantar warts, positive tuberculosis test r

106 bility of tableted diagnostics for screening hepatitis B-positive patient samples.

107 Hepatitis B reactivation associated with immune-suppress

108 ar mechanisms, prevention, and management of hepatitis B reactivation.

109 antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatit

110 follow-up period, of which none were due to hepatitis B recurrence.

111 C tissues and their clinical significance in hepatitis B-related HCC patients as revealed by our stud

112 ity of persons currently treated for chronic hepatitis B require long-term or lifelong therapy.

113 The adult cohort study of the Hepatitis B Research Network enrolls patients with HBV i

114 No patient with low Platelets, Age, Gender-Hepatitis B score at baseline or year 5 developed HCC.

115 Six patients had hepatitis B surface antibody (anti-HBs) titres above 10

116 hepatitis B surface antigen with or without hepatitis B surface antibody seroconversion, which is as

117 e the direct detection of antibodies against hepatitis B surface antigen (anti-HBs) in clinical serum

118 icting studies about whether the antibody to hepatitis B surface antigen (anti-HBs) protects against

119 chronic (current) infection; and antibody to hepatitis B surface antigen (anti-HBs), indicative of im

120 odds ratio for prevalent diabetes comparing hepatitis B surface antigen (HBsAg) (+) to HBsAg (-) par

121 Serologic HBV markers, including hepatitis B surface antigen (HBsAg) and e antigen (HBeAg

122 hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, wh

123 Among 2334 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients p

124 , R21 particles are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and

125 The age-specific seroclearance pattern of hepatitis B surface antigen (HBsAg) in chronic hepatitis

126 asured in cells, extracellular vesicles, and hepatitis B surface antigen (HBsAg) particles of hepatom

127 A total of 42 hepatitis B surface antigen (HBsAg) positive, human immu

128 g of adult community-based screening using a hepatitis B surface antigen (HBsAg) rapid test and subse

129 d communities in western Gambia were offered hepatitis B surface antigen (HBsAg) screening via a poin

130 The cumulative rates of hepatitis B surface antigen (HBsAg) seroclearance were 9

131 le HBV viral load, 7 had positive results on hepatitis B surface antigen (HBsAg) testing and had an u

132 Intradermal immunization of mice against hepatitis B surface antigen (HBsAg) using a novel real-t

133 The serum gradient of hepatitis B surface antigen (HBsAg) varies over time aft

134 reactivation and hepatitis we identified all hepatitis B surface antigen (HBsAg), HBV DNA, and alanin

135 -HBc), indicative of previous HBV infection; hepatitis B surface antigen (HBsAg), indicative of chron

136 ose with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), prevalent hepatic d

137 Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody t

138 tor high-risk children at 1 year of age with hepatitis B surface antigen and anti-hepatitis B to iden

139 HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with

140 ivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemothe

141 han genotype 1b, if they tested positive for hepatitis B surface antigen or anti-HIV antibody at scre

142 Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we de

143 ing those with human immunodeficiency virus, hepatitis B surface antigen positivity, hepatocellular c

144 apy, the estimated overall seroprevalence of hepatitis B surface antigen remains high at 6.1% (95% un

145 The cumulative rate of hepatitis B surface antigen seroclearance at 1, 5, and 1

146 Patients with positive anti-hepatitis B surface antigen serology were excluded.

147 n wild-type mice, and in mice that carried a hepatitis B surface antigen transgene-this to model the

148 Antibody to hepatitis B surface antigen was tested 1 month after the

149 onal cure characterized by sustained loss of hepatitis B surface antigen with or without hepatitis B

150 to hepatitis B core antigen, and antibody to hepatitis B surface antigen) for HBV in high-risk person

151 Practice Advice 2: Clinicians should screen (hepatitis B surface antigen, antibody to hepatitis B cor

152 e gold sensor surface and post modified with hepatitis B surface antigen.

153 In patients with chronic hepatitis B, TAF appears to be as effective as TDF, with

154 ent for individuals co-infected with HIV and hepatitis B, this regimen might lend itself to rapid or

155 ge with hepatitis B surface antigen and anti-hepatitis B to identify those with chronic HBV infection

156 omes, ranging from spontaneous resolution of hepatitis B to severe adverse consequences, including th

157 nce of the good immunogenicity and safety of hepatitis B vaccination among patients in China with chr

158 To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving me

159 a, and despite the introduction of universal hepatitis B vaccination and effective antiviral therapy,

160 oral and cell-mediated immunity responses to hepatitis B vaccination is still controversial.

161 es were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immuni

162 ndomized trials, and intervention studies on hepatitis B vaccination, screening, and linkage to care

163 icle to present best practice statements for hepatitis B vaccination, screening, and linkage to care.

164 atients had missed opportunities to initiate hepatitis B vaccination.

165 lmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mump

166 Hepatitis B vaccine is an effective measure to prevent h

167 >/=6 months using 3 doses of plasma-derived hepatitis B vaccine.

168 All participants received 3 doses of hepatitis B vaccine.

169 mong Asian/Pacific Islanders, chiefly due to hepatitis B vertical transmission, but other racial grou

170 med a case-cohort analysis of the effects of hepatitis B viral factors on risk for HCC, based on meta

171 (FISH)-based assay for the detection of duck hepatitis B virus (DHBV) cccDNA and HBV nuclear DNA in e

172 For the avian hepadnavirus duck hepatitis B virus (DHBV), CTD is dephosphorylated subseq

173 valence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.

174 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infe

175 uss common challenges to the burden posed by hepatitis B virus (HBV) and hepatitis C virus (HCV), to

176 Infections with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depe

177 tions and displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV)

178 transferase 1 (PRMT1) only modestly increase hepatitis B virus (HBV) biosynthesis.

179 been used to track the assembly of the T = 4 hepatitis B virus (HBV) capsid in real time.

180 ices to analyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical

181 The hepatitis B virus (HBV) causes acute and chronic liver i

182 Hepatitis B virus (HBV) chronic infection affects up to

183 Hepatitis B virus (HBV) chronically infects 250 million

184 rus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral th

185 HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with

186 tion state of the C-terminal domain (CTD) of hepatitis B virus (HBV) core or capsid protein is highly

187 Though the hepatitis B virus (HBV) core protein is an important par

188 tion and the factors involved.IMPORTANCE The hepatitis B virus (HBV) covalently closed circular (CCC)

189 Hepatitis B virus (HBV) covalently closed circular (CCC)

190 ified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affectin

191 ith nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affe

192 nd 95%, 99%, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

193 plantation, 39 (72%) patients had detectable hepatitis B virus (HBV) DNA, with a median of 4.5 log co

194 The management of hepatitis B virus (HBV) e antigen-positive viremic patie

195 Hepatitis B virus (HBV) encodes a multifunction reverse

196 To evaluate how hepatitis B virus (HBV) genetic variation affected progr

197 Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C

198 tion, and HBV-driven tumor growth.IMPORTANCE Hepatitis B virus (HBV) HBx protein plays a critical rol

199 Hepatitis B virus (HBV) immunization has been effectivel

200 dvice 1: Clinicians should vaccinate against hepatitis B virus (HBV) in all unvaccinated adults (incl

201 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the pres

202 Hepatitis B virus (HBV) infection afflicts millions worl

203 (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin

204 iral compounds.The lack of models that mimic hepatitis B virus (HBV) infection in a physiologically r

205 regarding the prevalence and distribution of hepatitis B virus (HBV) infection in U.S. Hispanics/Lati

206 Chronic hepatitis B virus (HBV) infection is a global public hea

207 Chronic hepatitis B virus (HBV) infection is a global public hea

208 Chronic hepatitis B virus (HBV) infection is a major risk factor

209 Hepatitis B virus (HBV) infection is a serious public he

210 Hepatitis B virus (HBV) infection is more common in Afri

211 Chronic hepatitis B virus (HBV) infection is partly responsible

212 A hallmark of chronic hepatitis B virus (HBV) infection is the functional impa

213 on or cirrhosis due to other causes, such as hepatitis B virus (HBV) infection or alcohol, remains un

214 he heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the complex ho

215 Hepatitis B virus (HBV) infection represents a significa

216 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in chil

217 Patients with resolved hepatitis B virus (HBV) infection who are treated for he

218 ions have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but little

219 th metabolic risk factors, for patients with hepatitis B virus (HBV) infection.

220 rcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

221 age to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

222 n patients with current or prior exposure to hepatitis B virus (HBV) infection.

223 patitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China remains uncl

224 BACKGROUND & AIMS: Hepatitis B virus (HBV) infects hepatocytes, but the mec

225 Hepatitis B virus (HBV) is a major global health concern

226 plication-competent viral capsids.IMPORTANCE Hepatitis B virus (HBV) is a major human pathogen, and n

227 Hepatitis B virus (HBV) is endemic in sub-Saharan Africa

228 Hepatitis B virus (HBV) modulates microRNA (miRNA) expre

229 We examined the associations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infec

230 ), most cases of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

231 -replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

232 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients

233 Hepatitis B virus (HBV) reactivation has been reported i

234 Hepatitis B virus (HBV) reactivation in hepatitis B surf

235 Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informati

236 ate cotransporting polypeptide (NTCP) as the hepatitis B virus (HBV) receptor enabled researchers to

237 an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantat

238 eraction mechanisms for achieving an optimal hepatitis B virus (HBV) replication have been largely un

239 Hepatitis B Virus (HBV) replication in hepatocytes is re

240 Persistent or chronic infection with the hepatitis B virus (HBV) represents one of the most commo

241 pies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status.

242 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhanci

243 New hepatitis B virus (HBV) therapies are expected to have b

244 Here, the CTD from the human hepatitis B virus (HBV) was found to be dephosphorylated

245 cquiring human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

246 f 47,591 adults wait-listed for LT from HCV, hepatitis B virus (HBV), and nonalcoholic steatohepatiti

247 Hepatitis B virus (HBV), belonging to Hepadnaviridae fam

248 role of the transcriptional template of the hepatitis B virus (HBV), covalently closed circular DNA

249 is in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver dise

250 th infections by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for th

251 Here, using mutational analyses of hepatitis B virus (HBV), we found that Hsp90 stimulates

252 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-associated cirrhosis and HBV-ass

253 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a

254 We have sampled healthy and hepatitis B virus (HBV)-infected human livers to probe f

255 disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer (NK) and

256 Activated and hepatitis B virus (HBV)-specific T cells, particularly t

257 cy virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV).

258 compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify

259 The study of hepatitis B virus and development of curative antivirals

260 es in the longer term through the control of hepatitis B virus and hepatitis C virus infections by va

261 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral

262 We also confirm suppression of hepatitis B virus and poliovirus by ARB.

263 on-Pfizer monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an

264 e show that cell-culture and patient-derived hepatitis B virus can establish persistent infection for

265 Chronic hepatitis B virus carriers are at risk of developing fib

266 Hepatitis B virus causes chronic infections in 250 milli

267 model of hepatitis B: infectious transgenic hepatitis B virus composed of a complete virus plus a fo

268 pid, high yield and economical production of Hepatitis B Virus core (HBc) particles.

269 s associated with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) s

270 for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with dev

271 will likely be needed to achieve functional hepatitis B virus cure.

272 The hepatitis B virus deploys the hepatitis B virus X protei

273 The peak levels of hepatitis B virus DNA and hepatitis B core-related antig

274 New inhibitors of hepatitis B virus entry, replication, assembly, or secre

275 The management for occupational HIV or hepatitis B virus exposures includes postexposure prophy

276 FNalpha was confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

277 A cross-sectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples wa

278 with HIV infection are at increased risk for hepatitis B virus infection.

279 B vaccine is an effective measure to prevent hepatitis B virus infection.

280 and obesity; 12.5% (95% CI: 10.6-14.3%) for hepatitis B virus infection; 29.1% (95% CI: 23.6-34.5%)

281 copies per mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing

282 For the discovery of hepatitis B virus integration sites from probe capture d

283 9 HDV-infected patients, 25 individuals with hepatitis B virus monoinfection and 18 healthy controls.

284 Formation of the hepatitis B virus nucleocapsid is an essential step in t

285 Chronic hepatitis B virus or hepatitis C co-infection was allowe

286 Patients with co-infection (hepatitis B virus or HIV infection), evidence of decompe

287 lly regulates several direct target genes of hepatitis B virus protein X (HBx), a viral co-factor.

288 Hepatitis B virus reactivation is a newly identified saf

289 Hepatitis B virus reactivation, defined as an abrupt inc

290 axis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately 2-5% of

291 yme as signal amplifier for determination of hepatitis B virus surface antigen (HBsAg).

292 in Egypt (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other Afr

293 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of hos

294 pentavalent (diphtheria, tetanus, pertussis, hepatitis B virus, and Haemophilus influenzae type b), y

295 tomegalovirus, human immunodeficiency virus, hepatitis B virus, and neonatal herpes simplex virus, fr

296 f viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, influenza virus, resp

297 re found in the sera from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic s

298 transfer of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell recepto

299 Hepatitis B viruses (HBVs), which are enveloped viruses

300 tion after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance rate of